http://online.wsj.com/article/PR-CO-20130603-905466.html?mod=googlenews_wsj
NEWARK, Calif.,(GLOBE NEWSWIRE) — StemCells, Inc. (Nasdaq:STEM) today announced that Health Canada has authorized the Company to expand its Phase I/II clinical trial for chronic spinal cord injury into Canada. The Phase I/II trial, currently underway in Zurich, Switzerland, is designed to evaluate the safety and preliminary efficacy…